Lipocine Inc at H C Wainwright NASH Investor Conference (Virtual) Transcript

Oct 12, 2021 / 07:30PM GMT
Wing Cheung Yip - H.C. Wainwright & Co, LLC, Research Division - Research Analyst

(technical difficulty) metabolic and endocrine disorders. Dr. Patel, Dr. Bruno, very good to have you with us. Please go ahead with your presentation.

Mahesh V. Patel - Lipocine Inc. - Co-Founder, Chairman, President & CEO

Thanks, Thomas. Thanks for the invitation. Good afternoon to all. I'm Mahesh Patel. I'm the President, CEO and Co-Founder of the company. I'm here to introduce you to the company and give you an update on our pipeline, and then I'll be passing over to Dr. Ben Bruno, who is our Director of Clinical Development, and he'll fill you in on the details of our liver asset programs in our pipeline.

Before we do that, some disclaimers on the forward-looking statement. I'll give you a few seconds to go over and dive straight into our pipeline. So Lipocine is a clinical stage biopharmaceutical company, with a focus on developing innovative products for metabolic and endocrine disorders. Very recently, we have branched and looked into opportunities in the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot